The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Potentially inappropriate prescribing and cost outcomes for older people: a national population study
Open accessAbstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Potentially inappropriate prescribing (PIP) refers to medications that should generally be avoided in older populations and doses or frequencies of administrations that should not be exceeded. Studies of PIP have been primarily based on US indicators of appropriateness such as the Beers criteria due to the lack of European specific indicators. • PIP has not been assessed in full national samples. • The total cost of PIP drugs and the cost in relation to overall national pharmaceutical expenditure have not been described. WHAT THIS STUDY ADDS • One third of the Irish population aged ≥70 years were prescribed at least one potentially inappropriate medication in 2007 based on European criteria. • There was a signficant association between polypharmacy and the risk of PIP. Polypharmacy was evaluated as the number of different repeat drug classes (≥ three prescription claims) per claimant. • The most prevalent PIP drugs were: proton pump inhibitors at maximum therapeutic dosage for >8 weeks (40 mg daily omeprazole, pantoprazole and esomeprazole, 30 mg daily lansoprazole and 20 mg daily rabeprazole); non‐steroidal anti‐inflammatories for >3 months; long‐acting benzodiazepines for >1 month and drug duplication within the same therapeutic class. • The total expenditure on potentially inappropriate drugs was €45 631 319 in 2007 which is 9% of the overall expenditure on pharmaceuticals in those aged ≥70 years in Ireland. AIMS Optimization of drug prescribing in older populations is a priority due to the significant clinical and economic costs of drug‐related illness. This study aimed to: (i) estimate the prevalence of potentially inappropriate prescribing (PIP) in a national Irish older population using European specific explicit prescribing criteria; (ii) investigate the association between PIP, number of drug classes, gender and age and; (iii) establish the total cost of PIP. METHODS This was a retrospective national population study (n= 338 801) using the Health Service Executive Primary Care Reimbursement Service (HSE‐PCRS) pharmacy claims database. The HSE‐PCRS uses the WHO Anatomical Therapeutic Chemical (ATC) classification system and details of every drug dispensed and claimants' demographic data are available. Thirty PIP indicators (STOPP) were applied to prescription claims for those ≥70 years in Ireland in 2007. STOPP is a physiological system based screening tool of older persons' potentially inappropriate prescriptions assessing drug–drug and drug–disease interactions, dose and duration. RESULTS In our study population PIP prevalence was 36% (121 454 claimants). The main contributors to this were: 56 560 (17%) prescribed proton pump inhibitors at maximum therapeutic dose for >8 weeks, 29 691 (9%) prescribed non‐steroidal anti‐inflammatories for >3 months, 17 676 (5%) prescribed long‐acting benzodiazepines for >1 month and 16 201 (5%) prescribed duplicate drugs. The main determinant of PIP was polypharmacy. The likelihood of PIP increased with a significant linear and quadratic trend (P < 0.0001) with the number of drug classes.The maximum net ingredient cost of PIP was estimated to be €38 664 640. Total PIP expenditure was estimated to be €45 631 319, 9% of the overall expenditure on pharmaceuticals in those ≥70 years in 2007. CONCLUSIONS The findings identify a high prevalence of PIP in Ireland with significant cost consequences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, B. K., & Breckenridge, A. M. (2004) · BMJ · doi:10.1136/bmj.329.7456.15 · Cited by 3,230
Fick, D. M., Cooper, J. W., Wade, W. E., Waller, J. L., Maclean, J. R., & Beers, M. H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.22.2716 · Cited by 2,389
Preventing Falls in Elderly Persons
Tinetti, M. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmcp020719 · Cited by 1,660
Gallagher, P., Ryan, C., Byrne, S., Kennedy, J., & OMahony, D. (2008) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp46072 · Cited by 1,506
Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture
Yang, Y.-X., Lewis, J. D., Epstein, S., & Metz, D. C. (2006) · JAMA · doi:10.1001/jama.296.24.2947 · Cited by 1,214
Appropriate prescribing in elderly people: how well can it be measured and optimised?
Spinewine, A., Schmader, K. E., Barber, N., Hughes, C., Lapane, K. L., Swine, C., & Hanlon, J. T. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61091-5 · Cited by 1,090
Potentially Inappropriate Medication Use Among Elderly Home Care Patients in Europe
Fialová, D. (2005) · JAMA · doi:10.1001/jama.293.11.1348 · Cited by 707
Gallagher, P., & O'Mahony, D. (2008) · Age and Ageing · doi:10.1093/ageing/afn197 · Cited by 697
Which drugs cause preventable admissions to hospital? A systematic review
Howard, R. L., Avery, A. J., Slavenburg, S., Royal, S., Pipe, G., Lucassen, P., & Pirmohamed, M. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02698.x · Cited by 625
Overprescribing proton pump inhibitors
Forgacs, I., & Loganayagam, A. (2008) · BMJ · doi:10.1136/bmj.39406.449456.be · Cited by 553
Cited by
Interventions to improve the appropriate use of polypharmacy for older people
Patterson, S. M., Cadogan, C. A., Kerse, N., Cardwell, C. R., Bradley, M. C., Ryan, C., & Hughes, C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008165.pub3 · Cited by 754
da Costa, B. R., Reichenbach, S., Keller, N., Nartey, L., Wandel, S., Jüni, P., & Trelle, S. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31744-0 · Cited by 522
RetractedInterventions to improve the appropriate use of polypharmacy for older people
Rankin, A., Cadogan, C. A., Patterson, S. M., Kerse, N., Cardwell, C. R., Bradley, M. C., Ryan, C., & Hughes, C. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008165.pub4 · Cited by 511
Gallagher, P. F., O'Connor, M. N., & O'Mahony, D. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.44 · Cited by 505
An overview of prevalence, determinants and health outcomes of polypharmacy
Khezrian, M., McNeil, C. J., Murray, A. D., & Myint, P. K. (2020) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620933741 · Cited by 443
Metadata
- Authors
- Cahir, C., Fahey, T., Teeling, M., Teljeur, C., Feely, J., & Bennett, K.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2010-04-12
- Volume
- 69
- Issue
- 5
- Pages
- 543-552
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1538368282
- Cited by
- 418
- References
- 41
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potentially inappropriate prescribing and cost outcomes for older people: a national population study. https://app.cochat.ai/papers/10.1111/j.1365-2125.2010.03628.x
- The paper
- Cahir, C., Fahey, T., Teeling, M., Teljeur, C., Feely, J., & Bennett, K. (2010). Potentially inappropriate prescribing and cost outcomes for older people: a national population study. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2010.03628.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.